BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alentis Therapeutics AG readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Alentis Therapeutics AG's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06747585-2338@assetmemo.bio
DTSTAMP:20261121T005945Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:ALE.P02: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:ALE.P02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Investigate ALE.P02 as a Monotherapy or in Combination With Pembroli
 zumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated prima
 ry completion: 15 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ale-p02#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/ale-p02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169734-2339@assetmemo.bio
DTSTAMP:20261121T005945Z
DTSTART;VALUE=DATE:20290405
DTEND;VALUE=DATE:20290406
SUMMARY:ALE.P03: Phase 1/2 readout est. (NCT07169734)
DESCRIPTION:ALE.P03\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected A
 dvanced or Metastatic CLDN1+ Solid Tumors\nEstimated primary completion: 5
  April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ale-p03#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0716
 9734
URL:https://assetmemo.bio/drug/ale-p03#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
